SCHEMBL5542220

SCHEMBL5542220

CCCCCCCCCc1ccc(-c2cc[c]cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.64
TSHR P16473 1/20 0.64
RARB P10826 9/20 0.57
ALDH1A1 P00352 3/20 0.57
MEN1 O00255 2/20 0.57
MAPT P10636 2/20 0.57
KMT2A Q03164 2/20 0.57
RARA P10276 2/20 0.57
MTOR P42345 1/20 0.57
ESR1 P03372 2/20 0.55
ADRA2A P08913 2/20 0.55
ADORA3 P0DMS8 2/20 0.55
TACR2 P21452 2/20 0.55
SLC6A2 P23975 2/20 0.55
SLC6A4 P31645 2/20 0.55
SLC6A3 Q01959 2/20 0.55
KDM4E B2RXH2 2/20 0.55
LMNA P02545 1/20 0.55
SHBG P04278 1/20 0.55
TP53 P04637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544425 1.00 HSD17B10 (0.64) HSD17B10TSHRRARBALDH1A1MEN1
SCHEMBL28518716 1.00 HSD17B10 (0.64) HSD17B10TSHRRARBALDH1A1MEN1
SCHEMBL17022435 1.00 HSD17B10 (0.64) HSD17B10TSHRRARBALDH1A1MEN1
SCHEMBL983507 1.00 HSD17B10 (0.64) HSD17B10TSHRRARBALDH1A1MEN1
SCHEMBL3090093 1.00 HSD17B10 (0.64) HSD17B10TSHRRARBALDH1A1MEN1
SCHEMBL981933 0.98 HSD17B10 (0.61) HSD17B10TSHRRARBALDH1A1MEN1
SCHEMBL6754529 0.92 RARB (0.55) HSD17B10TSHRRARBALDH1A1MEN1
SCHEMBL980959 0.92 RARB (0.55) HSD17B10TSHRRARBALDH1A1MEN1
SCHEMBL2967935 0.88 PTGS2 (0.57) HSD17B10TSHRALDH1A1ESR1ADRA2A
SCHEMBL225807 0.88 PTGS2 (0.57) HSD17B10TSHRALDH1A1ESR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
EP-0813571-A1 FLAME RETARDANT FOR STYRENE RESIN AND RESIN COMPOSITION COMPRISING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1997-12-29 EP disclosed
WO-1996027637-A1 FLAME RETARDANT FOR STYRENE RESIN AND RESIN COMPOSITION COMPRISING THE SAME ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1996-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HSD17B10 467/4885TSHR 319/4885RARB 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.